Baillie Gifford & CO Chinook Therapeutics, Inc. Transaction History

Baillie Gifford & CO

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 28, 2023	SELL	$18.66 - $38.58 $422,649 - $873,837	-22,650 Reduced 4.65%	463,945 $17.8 Million
Q1 2023 May 03, 2023	SELL	$21.53 - $26.8 $67,022 - $83,428	-3,113 Reduced 0.64%	486,595 $11.3 Million
Q4 2022 Jan 24, 2023	BUY	$18.63 - $27.35 $473,090 - $694,525	25,394 Added 5.47%	489,708 $12.8 Million
Q3 2022 Oct 27, 2022	SELL	$17.51 - $23.37 $709,347 - $946,742	-40,511 Reduced 8.02%	464,314 $9.13 Million
Q2 2022 Aug 08, 2022	SELL	$12.59 - $18.8 $3.85 Million - $5.75 Million	-306,054 Reduced 37.74%	504,825 $8.83 Million
Q1 2022 May 05, 2022	SELL	$12.02 - $16.69 $395,854 - $549,651	-32,933 Reduced 3.9%	810,879 $13.3 Million
Q4 2021 Jan 20, 2022	BUY	$10.69 - $16.83 $66,662 - $104,951	6,236 Added 0.74%	843,812 $13.8 Million
Q3 2021 Oct 19, 2021	SELL	$11.5 - $14.86 $20,746 - $26,807	-1,804 Reduced 0.21%	837,576 $10.7 Million
Q2 2021 Aug 02, 2021	SELL	$13.6 - $18.98 $83,028 - $115,872	-6,105 Reduced 0.72%	839,380 $11.9 Million
Q1 2021 May 06, 2021	BUY	$14.17 - $19.11 $11,350 - $15,307	801 Added 0.09%	845,485 $13.1 Million
Q4 2020 Feb 10, 2021	SELL	$11.9 - $20.91 $40.7 Million - $71.5 Million	-3,421,296 Reduced 80.2%	844,684 $13.4 Million
Q3 2020 Nov 12, 2020	BUY	$11.4 - $15.5 $48.6 Million - $66.1 Million	4,265,980 New	4,265,980 $10.4 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

Stay updated on Baillie Gifford & CO with notifications on news.